Antifibrotic Repurposing: How Finerenone Could Rejuvenate the Ovarian Niche and Restore Fertility in POI
Highlight
Breakthrough Discovery
Researchers identified finerenone, an FDA-approved mineralocorticoid receptor antagonist, as a potent agent for restoring follicle growth in premature ovarian insufficiency (POI) by targeting the ovarian microenvironment rather than the follicles themselves.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.